TCBP Responds to False Social Media Claim

Rhea-AI Summary

TC BioPharm (NASDAQ: TCBP) has officially refuted false social media claims regarding its potential delisting from Nasdaq. The company, which develops allogeneic gamma-delta T cell therapies, addressed rumors from a now-deleted social media post that incorrectly stated the company had filed an 8-K Notice to delist. TC BioPharm confirmed it remains fully compliant with all Nasdaq listing requirements and will continue trading on the exchange. The company indicated it will take action to defend against such misleading claims aimed at creating negative market dynamics.

Positive

• Company confirms full compliance with Nasdaq listing requirements
• Company maintains its Nasdaq listing status

Negative

• Company facing targeted misinformation affecting market perception

• TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange

EDINBURGH, Scotland, Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange. 

The since deleted rumor stated that the company had filed an 8-K Notice to "Delist" from the Nasdaq and would transfer trading to a different exchange. TC BioPharm reiterated that there is no truth to this remark and that TC BioPharm remains in compliance with all Nasdaq listing requirements. The Company will look to take action to defend itself from these types of these attacks which are perpetrated in an effort to create negative market dynamics. If you have any additional questions, please reach out to the company directly at ir@tcbiopharm.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-responds-to-false-social-media-claim-302287336.html

SOURCE TC BioPharm

FAQ

Is TC BioPharm (TCBP) being delisted from Nasdaq?

No, TC BioPharm has confirmed it is not being delisted and remains fully compliant with all Nasdaq listing requirements.

Did TC BioPharm (TCBP) file an 8-K Notice to delist from Nasdaq?

No, the company has confirmed this was a false claim spread on social media. No such filing was made.

What actions is TC BioPharm (TCBP) taking regarding false delisting claims?

The company stated it will take action to defend itself against false claims aimed at creating negative market dynamics.